Clinically, recombinant human EPO (rHuEPO) is widely used to treat anemia in patients with advanced chronic kidney disease or that induced by cancer and chemotherapy, particularly in cases of multiple myeloma (MM) and myelodysplastic syndromes (MDS) [4,5,6,7]. Here, EPO is linked to myelodysplastic syndrome.